EGFR and non-small cell lung carcinoma: A retrospective study of 122 EGFR-TKI-advanced EGFR-mutant NSCLC patients, especially with EGFR L858R mutation, revealed better mPFS (5.0 vs. 2.2 months) and mOS (14.4 vs. 7 months) in ICI-based combination therapy than that in ICI alone [45].